Librata Endometrial Ablation Device Treatment to Reduce Menstrual Blood Loss in Sites Across the United Kingdom
NCT ID: NCT02971189
Last Updated: 2016-11-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
40 participants
INTERVENTIONAL
2016-12-31
2017-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigators will also assess the secondary objectives of:
1. Rates of bleeding at months 3, 6 and 12 as measured by menstrual pictogram
2. Rate of serious adverse device effects through to day 30 post-operatively
3. Rates of re-intervention for menstrual related bleeding or pain and/or hysterectomy at 6 and 12 months
4. Rates of patient satisfaction at 6 and 12 months.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Librata endometrial ablation
Librata thermal balloon endometrial ablation treatment procedure will be performed in accordance with the physician's routine endometrial ablation practice and in accordance with the requirements of the LibrataTM IFU. The uterine cavity will be systematically inspected using hysteroscopy prior the ablative procedure (after any blind cervical dilatation) and post the ablative procedure to estimate the completeness of endometrial destruction and to exclude uterine trauma including uterine perforation. The patient will undergo standard post-operative monitoring and recovery according to usual hospital practices. An assessment will be made for any ablation procedure or device related serious adverse events.
Librata Endometrial Ablation
The treatment procedure will be performed in accordance with the physician's routine endometrial ablation practice and in accordance with the requirements of the LibrataTM IFU. The uterine cavity will be systematically inspected using hysteroscopy prior the ablative procedure (after any blind cervical dilatation) and post the ablative procedure to estimate the completeness of endometrial destruction and to exclude uterine trauma including uterine perforation. The patient will undergo standard post-operative monitoring and recovery according to usual hospital practices. An assessment will be made for any ablation procedure or device related serious adverse events.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Librata Endometrial Ablation
The treatment procedure will be performed in accordance with the physician's routine endometrial ablation practice and in accordance with the requirements of the LibrataTM IFU. The uterine cavity will be systematically inspected using hysteroscopy prior the ablative procedure (after any blind cervical dilatation) and post the ablative procedure to estimate the completeness of endometrial destruction and to exclude uterine trauma including uterine perforation. The patient will undergo standard post-operative monitoring and recovery according to usual hospital practices. An assessment will be made for any ablation procedure or device related serious adverse events.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Female subject from (and including) age 25 to 50 years
3. Uterine sound measurement between 6.0 to 10.0cm (external os to fundus).
4. A minimum menstrual blood loss of
* Menstrual Pictogram (MP) score of ≥150 for 3 consecutive months prior to study enrollment; OR,
* MP score ≥150 for one month for women who either had:
* at least 3 prior months documented failed medical therapy; or
* a contraindication to medical therapy; or
* refused medical therapy
5. Premenopausal at enrollment as determined by FSH measurement ≤ 40 IU/L
6. Not pregnant and no desire to conceive at any time
7. Subject agrees to use a reliable form of contraception. If a hormonal birth control method is used, the subject must have been on said method for ≥ 3 months prior to enrollment and agrees to remain on the same hormonal regimen through their study participation.
8. Able to provide written informed consent using a form that has been approved by the reviewing IRB/EC
9. Subject agrees to follow-up schedule and data collection requirements
10. Subject is literate or demonstrates an understanding on how to collect menstrual blood loss products, and use of the Menstrual Pictogram (MP) diary
Exclusion Criteria
2. Endometrial hyperplasia as confirmed by histology
3. Presence of active endometritis
4. Active pelvic inflammatory disease
5. Active sexually transmitted disease (STD), at the time of ablation.
* Note: Treatment of STD documented in the chart serves as sufficient evidence of infection resolution. Subject may be considered for study enrollment.
6. Presence of bacteraemia, sepsis, or other active systemic infection
7. Active infection of the genitals, vagina, cervix, uterus or urinary tract at the time of the procedure
8. Known/suspected gynecological malignancy within the past 5 years
9. Known clotting defects or bleeding disorders
10. Untreated/unevaluated cervical dyskaryosis (except CIN I)
11. Known or suspected abdominal/pelvic cancer
12. Prior uterine surgery (except lower segment caesarean section) that interrupts the integrity of the uterine wall (e.g., myomectomy or classical cesarean section)
13. Previous endometrial ablation procedure
14. Currently on medications that could thin the myometrial muscle, such as long-term steroid use (except inhaler or nasal therapy for asthma)
15. Currently on anticoagulants
16. Abnormal shaped uterine cavity as confirmed by transvaginal ultrasound scan +/- hysteroscopy - specifically:
* Septate or bicornuate uterus or other congenital malformation of the uterine cavity
* Submucosal fibroids (grade 0-2) which protrude \>1cm into the uterine cavity
* Polyps \> 2cm in maximum diameter
* Intramural or subserosal fibroid greater than 3 cm
17. Presence of an intrauterine device (IUD) which the subject unwilling to have removed at the time of the operative visit
18. Presence of an implantable contraceptive device (e.g. Essure or Adiana).
19. Subject not currently on hormonal birth control therapy and unwilling to use a non-hormonal birth control post-ablation.
20. Subject wanting concomitant hysteroscopic sterilization.
21. Subject who is within 6-weeks post-partum.
22. Any general health condition which, in the opinion of the Investigator, could represent an increased risk for the subject
23. Any subject who is currently participating or considers future participation in any other
25 Years
50 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Birmingham Women's NHS Foundation Trust
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mr.Justin Clark
Consultant Gynaecologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Justin Clark, MB ChB, MD
Role: PRINCIPAL_INVESTIGATOR
Birmingham Women's NHS Foundation Trust
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Shaw RW, Brickley MR, Evans L, Edwards MJ. Perceptions of women on the impact of menorrhagia on their health using multi-attribute utility assessment. Br J Obstet Gynaecol. 1998 Nov;105(11):1155-9. doi: 10.1111/j.1471-0528.1998.tb09968.x.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Birmingham WHC
Identifier Type: -
Identifier Source: org_study_id